Shots:

• AstraZeneca to receive up front & development- regulatory and commercial milestones along with royalties. The agreement will provide a novel compound into Sierra’s pipeline to supply therapies for patients with rare cancers
• Sierra plans to initiate a P-II study of momelotinib (JAK inhibitor) + AZD5153 (BRD4 BET inhibitor) in patients with myelofibrosis & will be responsible for global development. The trial is expected to start in H1’22
• Momelotinib is currently being evaluated in the P-III MOMENTUM clinical trial for symptomatic and anemic myelofibrosis patients and has received the US FDA’s FTD for the same. The results are expected in Q1’22

| Ref: Sierra Oncology | Image: Sierra Oncology